Clinical DevelopmentBioXcel Therapeutics announced details of the planned TRANQUILITY In-Care Phase 3 trial, indicating progress in their clinical development for the treatment of Alzheimer's disease agitation.
Financial HealthBioXcel Therapeutics' recent $25 million equity raise, expected to extend the company's cash runway into the fourth quarter of 2024, demonstrates strengthened financial stability.
Regulatory CollaborationThe TRANQUILITY In-Care trial's design, based on feedback from the FDA, showcases a collaborative effort with the agency to evaluate BXCL501's efficacy and safety.